18 May 2015

Director/PDMR Shareholding

RNS Number : 5346N
Verona Pharma PLC
18 May 2015
 

Verona Pharma plc

("Verona Pharma" or the "Company")

 

Director Dealings

 

 

18 May 2015, Cardiff - Verona Pharma plc (AIM: VRP) today received notification that on 15 and 18 May 2015 Directors of the Company purchased ordinary shares of 0.1 pence each of the Company ("Ordinary Shares"). The details of the trades are shown in the table below.

Director

Ordinary Shares Purchased

Date

Average Price (p)

Total interest in the Company

As a % of the total share capital

Dr. David Ebsworth

300,000

18/05/2015

3.50

3,579,774

0.35%

Dr. Jan-Anders Karlsson

135,000

15/05/2015

3.40

2,870,000

0.28%

Biresh Roy

150,000

18/05/2015

3.50

900,000

0.09%

 

 

-Ends-

 

 

For further information please contact:

 

Verona Pharma plc

Tel: +44 (0) 20 3283 4200

Jan-Anders Karlsson, CEO

 

 

 

N+1 Singer

Tel: +44 (0)20 7496 3000

Aubrey Powell / Jen Boorer

 

 

 

FTI Consulting

Tel: +44 (0)20 3727 1000

Julia Phillips / Simon Conway

 

 

 

Notes to Editors

 

About Verona Pharma plc

Verona Pharma plc is a UK-based clinical stage biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, asthma and cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase II trials as a nebulised treatment for acute exacerbations of COPD in the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma. Verona Pharma is also building a broader franchise around RPL554 to maximise its value, both to patients and to investors. This includes the very significant markets for COPD and asthma maintenance therapy. The Company is also exploring the potential of the drug in different diseases, such as cystic fibrosis, where it is in pre-clinical testing. 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSSFIFDAFISEDI

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

 

 

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us